Premium
Zoledronate Following Denosumab Discontinuation: Partial Reassurance but No Confidence
Author(s) -
Ferrari Serge
Publication year - 2020
Publication title -
journal of bone and mineral research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.882
H-Index - 241
eISSN - 1523-4681
pISSN - 0884-0431
DOI - 10.1002/jbmr.4022
Subject(s) - denosumab , medicine , discontinuation , osteoclast , bone remodeling , zoledronic acid , rankl , osteoporosis , blockade , urology , endocrinology , oncology , receptor , activator (genetics)